Eric Topol

And then you switched gears.

So tell us about that.

Well, I think that's perfect.

Curiosity driven science is not the term you often hear hypothesis driven, or now with AI, you hear more AI exploratory science, but, you know, no, that's great.

Now,

I want to get a little back to the AI story because it's so fascinating.

You use lots of different types of AI, such as cellular imaging, would be fusion models and drug discovery.

I mean, you've had drug discovery for different pathways.

You mentioned, of course, the ion channel.

And then also, as we touched on with your cell paper, the whole idea of

of targeting the cargo receptor with a small molecule, and then things in between.

So can you kind of, you discussed this, of course, at the London panel, but maybe you just give us the skinny on the different ways that you incorporate AI in the state of the art science that you're doing.

Oh, no question.

Now, it must be tough when you know the mechanism of these families' disease and you even have a drug candidate, but that it takes so long to go from that to helping these families and

What are your thoughts about that?

I mean, are you thinking also about genome editing for some of these diseases, or are you thinking to go through the route of, you know, here's a small molecule, here's the tox data in animal models, and here's phase one, and on and on?

Where do you think, because when you know so much, and then these people are suffering, how do you bridge that gap?

I have no doubts that you'll be doing this many times in your career.

No, there's no question about it.

It's extraordinary, actually.